Publications by authors named "Antti Hakalahti"
Article Synopsis
- The MANTRA-PAF study compares the effectiveness of radiofrequency catheter ablation (RFA) to antiarrhythmic drugs (AADs) for treating paroxysmal atrial fibrillation (PAF) as first-line therapy.
- The results showed that, after 24 months, patients in the RFA group had significantly lower AF burden and a higher percentage of being free from AF compared to those using AADs and those who crossed over to other treatments.
- Quality of life improved across all treatment groups with no significant differences in serious adverse events, suggesting that RFA could be a better first-line option for symptomatic PAF patients.
Aims: New evidence about first-line radiofrequency catheter ablation (RFA) in symptomatic atrial fibrillation (AF) has emerged. In a single study the comparative treatment effect is potentially diminished by the high rate of cross-over to the alternative therapy. Therefore, we conducted a systematic review and meta-analysis of the available data to further evaluate the efficacy and safety of RFA vs.
View Article and Find Full Text PDFAims: Current guidelines recommend discontinuation of oral anticoagulation treatment (OAT) and switch to heparin 2-5 days before catheter ablation of atrial fibrillation (AF). However, increasing evidence leans against the 'bridge therapy' and support continuation of OAT during the procedure.
Methods And Results: We evaluated the safety of AF ablation among patients with therapeutic OAT.